These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36807751)

  • 1. Paradigm guiding to tapering or discontinuation of biologic and targeted synthetic disease-modifying antirheumatic drugs in the treatment of patients with rheumatoid arthritis: Results from a local prospective study.
    Kaban N; Harman H
    Int J Rheum Dis; 2023 Apr; 26(4):689-698. PubMed ID: 36807751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort.
    Tageldin M; Wilson N; Yin Y; Sharma TS
    Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv8-iv13. PubMed ID: 37855679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic and targeted synthetic disease-modifying anti-rheumatic drugs improve body composition in rheumatoid arthritis patients more than conventional synthetic disease-modifying anti-rheumatic drugs: Results from the PRESENT study.
    Tada M; Matsumoto Y; Koike T; Mamoto K; Nakamura T; Anno S; Iida T; Goto H; Hidaka N
    Int J Rheum Dis; 2024 Oct; 27(10):e15371. PubMed ID: 39381837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
    Liang H; Danwada R; Guo D; Curtis JR; Kilpatrick RD; Hendrickson B; Islam SS
    RMD Open; 2019; 5(2):e001013. PubMed ID: 31673413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subsequent biologic and targeted synthetic disease modifying anti rheumatic drugs after fulfilling difficult-to-treat rheumatoid arthritis criteria: a survival analysis.
    Novella-Navarro M; Ruiz-Esquide V; López-Juanes N; Chacur CA; Monjo-Henry I; Nuño L; Peiteado D; Villalba A; Fernández-Fernandez E; Sanz-Jardón M; Kafati M; Sanmartí R; Plasencia-Rodríguez C; Balsa A
    Clin Rheumatol; 2024 Sep; 43(9):2817-2823. PubMed ID: 39009920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland.
    Burkard T; Vallejo-Yagüe E; Hügle T; Finckh A; Burden AM
    BMJ Open; 2022 Mar; 12(3):e056352. PubMed ID: 35292498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis.
    McDermott GC; DiIorio M; Kawano Y; Jeffway M; MacVicar M; Dahal K; Moon SJ; Seyok T; Coblyn J; Massarotti E; Weinblatt ME; Weisenfeld D; Liao KP
    Semin Arthritis Rheum; 2024 Jun; 66():152421. PubMed ID: 38457949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis.
    Lee BW; Lee JJ; Kim WU
    Korean J Intern Med; 2024 Sep; 39(5):833-844. PubMed ID: 38798047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
    Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
    Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review.
    Schlager L; Loiskandl M; Aletaha D; Radner H
    Rheumatology (Oxford); 2020 Feb; 59(2):324-334. PubMed ID: 31325305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower odds of remission among women with rheumatoid arthritis: A cohort study in the Swiss Clinical Quality Management cohort.
    Vallejo-Yagüe E; Pfund JN; Burkard T; Clair C; Micheroli R; Möller B; Finckh A; Burden AM
    PLoS One; 2022; 17(10):e0275026. PubMed ID: 36264948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
    Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
    Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: real-world data from the KOBIO Registry.
    Koh JH; Lee SK; Kim J; Kim HA; Shin K; Min JK
    Clin Exp Rheumatol; 2021; 39(2):269-278. PubMed ID: 32324126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs.
    Kalweit M; Burden AM; Boedecker J; Hügle T; Burkard T
    PLoS Comput Biol; 2023 Jun; 19(6):e1011073. PubMed ID: 37267387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors.
    Arnold S; Jaeger VK; Scherer A; Ciurea A; Walker UA; Kyburz D
    Rheumatology (Oxford); 2021 Dec; 61(1):131-138. PubMed ID: 33848332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis.
    Uhrenholt L; Christensen R; Dinesen WKH; Liboriussen CH; Andersen SS; Dreyer L; Schlemmer A; Hauge EM; Skrubbeltrang C; Taylor PC; Kristensen S
    Rheumatology (Oxford); 2022 Aug; 61(8):3107-3122. PubMed ID: 34864896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lowering Expectations: Glucocorticoid Tapering Among Veterans With Rheumatoid Arthritis Achieving Low Disease Activity on Stable Biologic Therapy.
    Wallace BI; England BR; Baker JF; Rojas J; Sauer BC; Roul P; Kunkel GA; Braaten TJ; Petro A; Mikuls TR; Cannon GW
    ACR Open Rheumatol; 2023 Sep; 5(9):437-442. PubMed ID: 37491906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient perspectives on tapering biologic or targeted synthetic therapy in well-controlled rheumatoid arthritis and comparison with providers' perspectives.
    Wiemer N; Webster P; Attur M; Yin Y; Sharma T
    Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv3-iv7. PubMed ID: 37855678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
    Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
    Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Canadian Retrospective Chart Review Evaluating Concomitant Methotrexate De-escalation Patterns in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARDs.
    Bessette L; Florica B; Naik L; Sholter D; Fournier PA; Girard T; Liazoghli D; Baer PA
    Rheumatol Ther; 2024 Oct; 11(5):1165-1180. PubMed ID: 38976169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.